A look at oral GLP-1 pill data and how pill-based options could expand access versus injectables.
Key Takeaways
- HRS-7535 produced 11.1% average weight loss by week 50 versus 2.6% placebo
- In diabetes patients, HRS-7535 lowered HbA1c by 1.50%–1.68% across doses
- Highest HRS-7535 dose outperformed dapagliflozin on glycemic control